At UCB, our purpose is to create value for patients now and in the future. We fulfill this purpose by elevating the lives of patients and their families through our medicines, creating positive change across society.

Each year, we strive to enhance the lives of people living with severe neurological, immunological, and rare conditions. As we inch closer to a new year, it is important to reflect on our achievements – from launching new medications to clinical trial successes to research advances – 2024 was another year illustrative of our unwavering commitment to the patients we serve.

Differentiating with Science

We are rooted in creating solutions that improve the lives of people living with severe neurological and immunological diseases. Our investment in scientific innovation is nearly 30% of our overall revenue, and we incorporate the individual experiences of patients and caregivers into the discovery, development, and delivery of our medicines. Their insights inform our solutions for specific patient populations, including rare patient populations, and provide positive impact for patients and society.

Over the last year and a half, we received six FDA approvals (five indications and a new formulation) for one of our immunological medicines that treats psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and most recently, hidradenitis suppurativa, which often is a chronic, recurring, painful, and potentially debilitating inflammatory skin disease.

We also made our newest treatment for generalized myasthenia gravis commercially available in the U.S. We also offer patients the first targeted therapy for MuSK positive patients, and the first subcutaneous self-administered injection, offering patients an option to administer their medication at home. Now we can offer physicians and patients a portfolio of medicines in gMG with two different mechanisms of actions and two different methods of administration.

This was in addition to numerous other approvals and launches from UCB around the world.

Driving Value through Results

The value of our medicine comes in many forms, including the overall impact a treatment has on people living with severe diseases, their caretakers, and the healthcare system. To respond to specific patient needs, we offer support services to help patients who have been prescribed our products and may face barriers to accessing or affording needed medicines.

Additionally, in 2024, we partnered with the Lennox-Gastaut Syndrome (LGS) Foundation and Dravet Syndrome (DS) Foundation to compile the Siblings Voices Survey. This survey assesses how children adapt to growing up with siblings living with a rare form of epilepsy. Results from the survey informed our VIP Sibling Project – a portfolio of resources to support siblings, parents, and caregivers of people living with a rare epilepsy syndrome. As part of the program, UCB collaborated with 10 dedicated patient organizations of the rare epilepsy community to create the C.A.R.E Binder, an interactive, fillable PDF resource has been created to support families as they begin to work through long‐term adult care planning for their loved one with a rare epilepsy.
 

Succeeding Together

Our work extends beyond developing new medicines. We strive to create sustainable impact for people living with severe disease and society by addressing unmet patient needs, improving health equity, and minimizing our environmental impact.

As a part of our commitment to bringing solutions to people living with severe disease, UCB collaborated with The Health Policy Partnership to publish a comprehensive report titled "Call to Action: Improving the Lives of People with Hidradenitis Suppurativa." This report communicates the condition’s significant impact and advocates for change by highlighting policy and system barriers to better HS care.  We also hosted the inaugural UCB HS Summit in August of this year, fostering discussions among patients, caregivers, advocacy leaders, and healthcare providers to better understand the HS treatment journey and identify unmet needs.

This fall, we also launched the UCB Myasthenia Gravis Scholarship to help individuals living with myasthenia gravis (MG) and their immediate family members to pursue educational opportunities such as studies in trade skills, college courses or any other disciplines. The scholarship, which builds on the company’s success of the UCB Family Epilepsy Scholarship Program™ will award recipients to help  ease the costs associated with education, such as tuition, fees, room and board, and other additional costs.
 
In 2024, we pushed the boundaries of scientific innovation, delivered value to our patients, and focused on creating sustainable impact for people living with severe disease. However, our work is far from over. While we close the chapter on 2024, we’re energized and poised to continue delivering the moments that matter to even more people living with severe diseases in 2025.